{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:36:41Z","timestamp":1784547401492,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hospital Management Research Foundation of the General Hospital of Western Theater Command","award":["2019ZY06"],"award-info":[{"award-number":["2019ZY06"]}]},{"name":"Hospital Management Research Foundation of the General Hospital of Western Theater Command","award":["2021-XZYG-A07"],"award-info":[{"award-number":["2021-XZYG-A07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>An atypical BCR::ABL1 fusion gene transcript in chronic myeloid leukemia (CML) patients, even those with variant Philadelphia (Ph) chromosome translocation, is very rare. In the present study, we report a case of CML (41 years, female) with extreme thrombocytosis at onset, with the variant Ph chromosome and rare e14a3 (b3a3) BCR::ABL1 transcript. The patient was prescribed imatinib as a first-line therapy and subsequently achieved complete hematologic remission within 2 months and major molecular response (MMR) within 3 months, and the transcript was undetectable within half a year. During up to nine years of follow-up, the quantification of this rare fusion gene was consistently negative with no BCR::ABL1 kinase domain mutations. Furthermore, we collected previously reported CML cases with the e14a3 (b3a3) transcript that indicated that the e14a3 (b3a3) transcripts appeared to have a larger number of thrombocytosis and variant Ph translocations than CML in general. This subgroup of CML might have better responses and outcomes to imatinib than patients with common transcripts.<\/jats:p>","DOI":"10.3390\/curroncol29110645","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:45:00Z","timestamp":1667087100000},"page":"8171-8179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report"],"prefix":"10.3390","volume":"29","author":[{"given":"Xupai","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoping","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.3109\/10428194.2014.909038","article-title":"Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"55","author":"Sora","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5045\/kjh.2012.47.1.7","article-title":"Chronic myeloid leukemia with extreme thrombocytosis","volume":"47","author":"Kim","year":"2012","journal-title":"Korean J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: Data from a single centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","article-title":"Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: A multi-institutional study from the bone marrow pathology group","volume":"31","author":"Soderquist","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/bcj.2015.77","article-title":"Concomitant JAK2 V617F-Positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib","volume":"5","author":"Zhou","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1309\/AJCPALP51XDIXDDV","article-title":"The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms","volume":"144","author":"Lin","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.2147\/OTT.S142587","article-title":"Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors","volume":"10","author":"Liu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00277-004-0877-4","article-title":"Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: Natural history and diagnostic differentiation from Ph-negative essential thrombocythemia","volume":"83","author":"Michiels","year":"2004","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V64.1.1.1","article-title":"Bleeding and thrombosis in the myeloproliferative disorders","volume":"64","author":"Schafer","year":"1984","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V100.2.435","article-title":"Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months\u2019 experience","volume":"100","author":"Braziel","year":"2002","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2008.01.005","article-title":"Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy","volume":"182","author":"Richebourg","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome","volume":"125","author":"Kantarjian","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.3109\/10428194.2015.1037751","article-title":"Chronic myeloid leukemia with e14a3 BCR-ABL transcript: Analysis of characteristics and prognostic significance","volume":"56","author":"Gui","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","first-page":"5619","article-title":"How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review","volume":"14","author":"Hu","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13039-016-0257-5","article-title":"A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia","volume":"9","author":"Lyu","year":"2016","journal-title":"Mol. Cytogenet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000490697","article-title":"Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR\/ABL Rearrangement Presenting with Thrombocytosis - Does MTHFR Polymorphism Matter","volume":"11","author":"Chisti","year":"2018","journal-title":"Case Rep. Oncol."},{"key":"ref_26","first-page":"2648","article-title":"Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report","volume":"18","author":"Massimino","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000494427","article-title":"Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR\/ABL Fusion Transcript","volume":"141","author":"Swaminathan","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e3276","DOI":"10.1002\/jgm.3276","article-title":"Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing","volume":"23","author":"Zhao","year":"2021","journal-title":"J. Gene. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1155\/2013\/691326","article-title":"Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: The threats and challenges in monitoring minimal residual disease (MRD)","volume":"36","author":"Vaniawala","year":"2013","journal-title":"Anal. Cell Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2015.08.017","article-title":"ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell","volume":"369","author":"Liu","year":"2015","journal-title":"Cancer Lett."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:15Z","timestamp":1760144715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110645"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110645","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}